. Author manuscript; available in PMC: 2020 Jul 30.

Published in final edited form as: J Am Coll Cardiol. 2019 Jul 30;74(4):567–577. doi: 10.1016/j.jacc.2019.06.007

Table 4:

Selected Research Questions Regarding CHIP-Associated Cardiovascular Complications

• Does cardiovascular risk and pathogenic mechanisms in CHIP vary with the gene mutated or the specific mutation?

• Can therapeutic interventions (e.g. lifestyle modification, medications) alter cardiovascular risk in CHIP, and do so in a mutation dependent manner?

• Should the VAF of the mutant gene in CHIP be used in clinical decision making?

• To what degree does CHIP interact with other risk factors for cardiovascular disease, including genetic predisposition.

• What populations can benefit for screening for CHIP?

• At what intervals should individuals with CHIP have follow-up from a clinical effectiveness perspective?

• What pathways prove most clinically effective for CHIP carriers with a known/prior malignancy? Should these pathways differ from patients without a cancer diagnosis?